What's new in sarcoidosis?

Rheumatoid Arthritis Comorbidities

Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.

Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders

  Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.

DMARDS, Prednisone, Pregnancy, OH MY!

Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos. 

Sarcopenia

Breathing New Insight into RA Interstitial Lung Disease

Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.

EULAR 2022 - Day 4 Faculty Panel Recap

Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.

Getting to the Heart of JAK Inhibitors

Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269. 

EULAR 2022 - Day 3 Faculty Panel Recap

Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.

Deucravacitinib at EULAR 2022

Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0